Partners sought for AMP-based biotech platform against antimicrobial resistance

BIOMECORP is a biotechnology SME based in Türkiye and located at TÜBİTAK Marmara Technopark. The company develops biologically programmed functional biotech platforms with a strong focus on antimicrobial resistance, natural immunity mechanisms, and antimicrobial peptide-enriched biological products.

BIOMECORP was selected as a Hello Tomorrow Deep Tech Pioneer in 2026 and has received business development support under the KOSGEB Entrepreneurship Support Programme. The company is currently building international R&D collaborations and preparing project applications under European and national innovation programmes.

Our proposed project aims to develop a Tenebrio molitor-based biological production platform that can generate antimicrobial peptide-rich biomass and extracts after controlled biological stimulation. The long-term objective is to create a scalable, standardised and commercially translatable biotech platform that may support the development of next-generation alternatives to conventional antimicrobial approaches.

The proposed R&D work focuses on:

• biological programming of Tenebrio molitor for enhanced antimicrobial peptide response,

• extraction and characterisation of antimicrobial peptide-rich fractions,

• activity screening against relevant resistant bacterial pathogens,

• process optimisation and batch-to-batch standardisation,

• safety, stability and quality control studies,

• development of potential applications in veterinary biotechnology, functional feed, antimicrobial research and life sciences.

We are looking for international partners for a Eureka Biotech Call 2026 project, especially:

• biotechnology SMEs working on antimicrobial resistance,

• universities or research centres with expertise in antimicrobial peptide characterisation,

• clinical microbiology or veterinary microbiology laboratories,

• CROs or laboratories capable of antibacterial activity testing against resistant strains,

• partners experienced in LC-MS/MS, proteomics, bioinformatics or peptide analytics,

• bioprocess scale-up, formulation or regulatory/commercialisation experts.

BIOMECORP can contribute with the core biological production concept, Tenebrio molitor-based platform development, experimental design, early-stage production know-how, and commercialisation vision. We aim to build a collaborative project addressing antimicrobial resistance through innovative, biologically derived antimicrobial technologies.